Clinical Trial Detail

NCT ID NCT02785068
Title Evaluation of MM-151 + Nal-IRI + 5-FU + Leucovorin in RAS/RAF Wild-type Metastatic Colorectal Cancer
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Merrimack Pharmaceuticals
Indications

colorectal cancer

Therapies

Fluorouracil + Irinotecan + Leucovorin + MM-151

Age Groups: adult senior

Additional content available in CKB BOOST